Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

BioLineRx Ltd. (BLRX)

Add BLRX Price Alert      Hide Sticky   Hide Intro
Moderator: midastouch017
Search This Board: 
Last Post: 11/22/2017 8:50:09 AM - Followers: 95 - Board type: Free - Posts Today: 0

BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.

BioLineRx's close ties with universities, research institutes, academic institutions, technology transfer offices and biotechnology companies, both in Israel and globally, enable access to promising projects at an early stage. The first stage involves a stringent selection process. BioLineRx's scientists specialize in evaluating potential drug candidates from both scientific and marketing perspectives. After acquiring the most promising projects, the Company then performs feasibility assessment studies and development through pre-clinical and clinical stages. Supported and assisted by a distinguished panel of scientific advisers, the Company's scientists and experts in pharmacy and regulation, clinical trials and IP work together to advance BioLineRx’s pipeline usually through Phase II proof of concept in humans. And finally, the Company partners with medium size and large pharmaceutical companies to complete the clinical development and bring the product to market.
BioLineRx also operates BioLine Innovations Jerusalem (BIJ) a biotechnology incubator for the development of pre-clinical therapeutic candidates, and an Early Development Program (EDP) dedicated to identifying and advancing promising early stage programs.



BL-7040 (IBD) – Received positive results from a Phase 2 proof-of-concept study to evaluate the effectiveness of BL-7040 for the treatment of inflammatory bowel disease (IBD)

Immediate next steps include evaluating the most advantageous ways to progress with this therapeutic candidate from a clinical and business perspective, including examining potential additional indications. Plans also include accelerating discussions with potential co-development and licensing partners.

BL-8040 (AML) – Received U.S. regulatory approvals to commence a Phase 2a trial for the treatment of relapsed/refractory acute myeloid leukemia (AML); trial to be conducted at three sites in the U.S. and five sites in Israel, with initial patient enrollment expected in Q2 2013; partial results expected in Q4 2013 and final results expected in the second half of 2014

BL-1040 (ventricular remodeling) – Recruitment commenced at U.S. sites for the PRESERVATION I clinical trial, a CE Mark registration trial for BL-1040 (BCM), a novel medical device for the prevention of ventricular remodeling following an acute myocardial infarction; there are currently multiple active sites recruiting in six countries

BL-5010 (skin lesions) – Reached final stages of development for proprietary pen-like applicator for BL-5010, a novel formulation of two acids being developed for the non-surgical removal of skin lesions; planning to commence pivotal CE-Mark registration trial for European approval in the second half of 2013

BL-8020 (HCV) – Commenced a Phase 1/2 clinical trial to evaluate the effectiveness of an orally-available, interferon-free treatment for Hepatitis C (HCV) at two sites in France, following approval from the French regulatory authorities; partial results expected in Q4 2013; final results expected in the first half of 2014

BL-1020 (schizophrenia) – Disappointing results of interim analysis for the Phase 2/3 CLARITY trial led to termination of the trial; full unblinded study data is expected during Q3 2013

BL-9010 (severe asthma) – Added a novel, bi-specific antibody for the treatment of severe and persistent asthma to the main therapeutic pipeline, following promising pre-clinical data

Capital Raise – $8 million direct equity placement to the OrbiMed Group was completed in February 2013

“In the past few months, we have seen major progress on a number of clinical and pre-clinical programs in our pipeline, which offer exciting opportunities to address unmet medical needs in a wide range of therapeutic areas. We believe our active programs offer significant potential for patients around the world, as well as for the future success of our Company and its shareholders,” stated Kinneret Savitsky, Ph.D, Chief Executive Officer of BioLineRx. “In the third quarter of this year, we expect to receive a full analysis of the unblinded study data for all participants in the CLARITY Phase 2/3 trial for BL-1020. While we discontinued this clinical trial in mid-March based on disappointing results of the interim analysis, we will not decide the future of the overall BL-1020 program until we have carried out a more thorough review of the full unblinded results.”

“The PRESERVATION I study being conducted by our partner, Ikaria, for BL-1040, for the treatment of ventricular remodeling post-AMI, is moving forward at full steam, with multiple sites in six countries around the world actively recruiting, including a number of sites in the U.S. BL-1040 remains one of our leading compounds, with significant clinical data expected to be reported next year, and we hope that it will eventually offer a great benefit to heart attack patients,” continued Dr. Savitsky.

“We continue to accelerate development of our clinical pipeline, with three of our compounds completing significant milestones since the beginning of the year. Our BL-7040 compound for IBD completed a Phase 2a open-label, proof-of-concept study with very encouraging and positive results. We are now evaluating next steps for BL-7040 in order to identify the best way to move forward from both a clinical and business perspective, including examining potential additional indications. In parallel, we are also planning to accelerate discussions with potential co-development and licensing partners for this asset.”

“In addition, BL-8040, for hematological cancers, one of our most exciting programs, just received FDA approval to commence a Phase 2a trial for the treatment of relapsed/refractory AML. We are excited to initiate this multicenter, open-label study under an IND, which will be conducted in the U.S. and Israel, and will enroll up to 50 patients. MD Anderson Cancer Center in Houston will be the initial site for this trial, with two additional premier sites in the US and five other well-known sites in Israel expected to participate. We believe the excitement surrounding the trial, especially at these particular sites, is a testament to the need for an AML therapy, as well as the potential of BL-8040 shown in the previous pre-clinical and clinical data.”

“Finally, we recently reported enrollment of the first patient in our Phase 1/2 trial for BL-8020, an oral treatment for HCV, at a leading hospital in Paris, France. We look forward to partial results from the trial in the fourth quarter of 2013, as well as final results in the first half of 2014. I would also like to point out that as our pipeline evolves, we continue to replenish our pre-clinical pipeline with the addition of promising assets, such as BL-9010 for the treatment of severe and persistent asthma, which recently graduated from our Early Development Program,” concluded Dr. Savitsky

Link To Interview with BioLineRX VP Of Business Development: -  BioLineRX Website

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BLRX News: Report of Foreign Issuer (6-k) 11/21/2017 07:01:41 AM
BLRX News: BioLineRx Reports Third Quarter 2017 Financial Results 11/21/2017 07:00:00 AM
BLRX News: Report of Foreign Issuer (6-k) 11/20/2017 07:01:45 AM
BLRX News: BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers S... 11/20/2017 07:00:00 AM
BLRX News: BioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New York 11/16/2017 07:00:00 AM
#1612   BioLineRx's (BLRX) CEO Philip Serlin on Q3 2017 midastouch017 11/22/17 08:50:09 AM
#1611   they still have 55 million cash with burning dave86 11/21/17 01:02:04 PM
#1610   You admitted losing in BLRX, midastouch017 11/21/17 11:58:27 AM
#1609   Realist of the Year right here! Lol Dizzle96 11/21/17 11:56:13 AM
#1608   You're right cause they won't move anyways Dizzle96 11/21/17 11:55:04 AM
#1607   BioLineRx Reports Third Quarter 2017 Financial Results midastouch017 11/21/17 07:55:44 AM
#1606   Here we go again, loser and midastouch017 11/21/17 12:01:50 AM
#1605   Stocks like these need no pumping dave86 11/20/17 11:58:52 PM
#1604   Oh jeez here we go again! Pumper of Dizzle96 11/20/17 04:41:52 PM
#1603   BioLineRx Ltd. (BLRX) Receives Average Recommendation of “Buy” midastouch017 11/20/17 08:28:51 AM
#1602   BioLineRx Announces Partial Results of BL-8040 COMBAT Study midastouch017 11/20/17 08:25:33 AM
#1601   This stock is indeed not for the faint midastouch017 11/16/17 03:35:20 PM
#1600   Hi Midas: Our bets are in and our shub 11/16/17 03:30:21 PM
#1599   Fully agreed. Risk/Reward midastouch017 11/16/17 03:18:44 PM
#1598   It's sure cheap now! shub 11/16/17 03:06:06 PM
#1597   BioLineRx Ltd. to Host Investor Breakfast Meeting December midastouch017 11/16/17 07:36:48 AM
#1596   Lmao. Pumped on iHub. Dime a dozen imo Rogerthat1 11/15/17 06:16:23 PM
#1595   And this one here you are pumping a Dizzle96 11/15/17 04:31:21 PM
#1593   Hhhmmmmm...... So far I've been right Dizzle96 11/15/17 04:29:06 PM
#1591   MM playing with emotion for Nov 21 ER. Bornagain777 11/14/17 09:18:50 PM
#1590   THIS STOCK MUST HAVE SOME BIG SKELETONS IN chevelle 396 11/14/17 05:58:24 PM
#1589   I added at 1.01 this morning and this dave86 11/14/17 02:13:55 PM
#1588   I AGREE , I AM JUST HOPING TO sell sell 11/14/17 12:48:40 PM
#1587   Yeah I think I'm going to try and dave86 11/14/17 03:16:45 AM
#1586   Lipped under $1 today for a second there. Dizzle96 11/13/17 04:04:48 PM
#1585   They have plenty of cash with no debt dave86 11/09/17 02:59:22 PM
#1584   Not yet. I hear ya. GolfFishSurf 11/09/17 12:34:25 PM
#1583   Anyone respond to this question ? Dizzle96 11/09/17 11:01:18 AM
#1582   Just checking, are we at $3 yet? Dizzle96 11/09/17 11:00:32 AM
#1581   I added a bunch @ 1.04 the other dave86 11/03/17 05:45:14 PM
#1580   Hi Midas: shub 11/03/17 02:30:10 PM
#1579   SITC 2017 midastouch017 11/03/17 12:12:32 AM
#1578   Midas, do you know the exact date and Bornagain777 11/02/17 07:07:49 PM
#1577   iPharma Enters Into Licensing Agreement With Boehringer Ingelheim midastouch017 11/02/17 12:19:40 PM
#1576   BLRX: BioLineRx Announces Oral Presentation at ASH of midastouch017 11/02/17 09:02:45 AM
#1575   Would you happen to know the exact date Bornagain777 10/24/17 04:36:37 PM
#1574   Upgrade by Oppenheimer. Just can't see the Hopeful1037 10/18/17 09:27:21 PM
#1573   BioLineRx Announces Initiation of Phase 1b/2 Trial for Amatuer17 10/18/17 08:34:04 AM
#1571   A non specific response. shub 10/09/17 03:51:20 PM
#1570   Zacks Investment Research Upgrades Bioline RX midastouch017 10/08/17 11:06:00 AM
#1569   As long as the stock is on the midastouch017 10/05/17 10:50:59 PM
#1567   Oh ya and since it's a perfect place, Dizzle96 10/05/17 06:47:25 PM
#1566   They're all the same!! Lol and they're working Dizzle96 10/05/17 06:46:44 PM
#1565   EXACTLY!!!!!! Dizzle96 10/05/17 06:45:56 PM
#1564   You make no sense Dizzle96 10/05/17 06:45:37 PM
#1562   "Fraud alert" he says. shub 10/04/17 02:20:07 PM
#1561   No war presently. More than i can say shub 10/04/17 02:17:41 PM
#1560   Why so stagnant? Where's the 'Outperform" and $3 GolfFishSurf 10/02/17 02:47:41 PM
#1559   BioLineRx Announces Initiation of Phase 1b/2 Trial for midastouch017 09/26/17 08:24:31 AM
#1556   Better late than never. Dubb10 09/21/17 11:37:21 AM